[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

EP1929291A4 - ESTRIOL THERAPY FOR DISEASE OF AUTOIMMUNE AND NEURODEGENERATIVE DISORDERS - Google Patents

ESTRIOL THERAPY FOR DISEASE OF AUTOIMMUNE AND NEURODEGENERATIVE DISORDERS

Info

Publication number
EP1929291A4
EP1929291A4 EP06815626A EP06815626A EP1929291A4 EP 1929291 A4 EP1929291 A4 EP 1929291A4 EP 06815626 A EP06815626 A EP 06815626A EP 06815626 A EP06815626 A EP 06815626A EP 1929291 A4 EP1929291 A4 EP 1929291A4
Authority
EP
European Patent Office
Prior art keywords
autoimmune
disease
neurodegenerative disorders
estriol
therapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP06815626A
Other languages
German (de)
French (fr)
Other versions
EP1929291A2 (en
Inventor
Rhonda R Voskuhl
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California Berkeley
University of California San Diego UCSD
Original Assignee
University of California Berkeley
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California Berkeley, University of California San Diego UCSD filed Critical University of California Berkeley
Priority to EP16000349.7A priority Critical patent/EP3045177A1/en
Priority to EP13005320.0A priority patent/EP2698167A3/en
Publication of EP1929291A2 publication Critical patent/EP1929291A2/en
Publication of EP1929291A4 publication Critical patent/EP1929291A4/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
EP06815626A 2005-09-26 2006-09-26 ESTRIOL THERAPY FOR DISEASE OF AUTOIMMUNE AND NEURODEGENERATIVE DISORDERS Ceased EP1929291A4 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP16000349.7A EP3045177A1 (en) 2005-09-26 2006-09-26 Estriol therapy for autoimmune and neurodegenerative diseases and disorders
EP13005320.0A EP2698167A3 (en) 2005-09-26 2006-09-26 Dosage form of an estriol and glatiramer acetate polymer-1 for the treatment of multiple sclerosis

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US72097205P 2005-09-26 2005-09-26
US83352706P 2006-07-26 2006-07-26
PCT/US2006/037752 WO2007038636A2 (en) 2005-09-26 2006-09-26 Estriol therapy for autoimmune and neurodegenerataive diseases and disorders

Related Child Applications (2)

Application Number Title Priority Date Filing Date
EP16000349.7A Division EP3045177A1 (en) 2005-09-26 2006-09-26 Estriol therapy for autoimmune and neurodegenerative diseases and disorders
EP13005320.0A Division EP2698167A3 (en) 2005-09-26 2006-09-26 Dosage form of an estriol and glatiramer acetate polymer-1 for the treatment of multiple sclerosis

Publications (2)

Publication Number Publication Date
EP1929291A2 EP1929291A2 (en) 2008-06-11
EP1929291A4 true EP1929291A4 (en) 2010-12-22

Family

ID=37900442

Family Applications (3)

Application Number Title Priority Date Filing Date
EP13005320.0A Withdrawn EP2698167A3 (en) 2005-09-26 2006-09-26 Dosage form of an estriol and glatiramer acetate polymer-1 for the treatment of multiple sclerosis
EP06815626A Ceased EP1929291A4 (en) 2005-09-26 2006-09-26 ESTRIOL THERAPY FOR DISEASE OF AUTOIMMUNE AND NEURODEGENERATIVE DISORDERS
EP16000349.7A Withdrawn EP3045177A1 (en) 2005-09-26 2006-09-26 Estriol therapy for autoimmune and neurodegenerative diseases and disorders

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP13005320.0A Withdrawn EP2698167A3 (en) 2005-09-26 2006-09-26 Dosage form of an estriol and glatiramer acetate polymer-1 for the treatment of multiple sclerosis

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP16000349.7A Withdrawn EP3045177A1 (en) 2005-09-26 2006-09-26 Estriol therapy for autoimmune and neurodegenerative diseases and disorders

Country Status (5)

Country Link
EP (3) EP2698167A3 (en)
JP (1) JP2009510084A (en)
AU (1) AU2006294662A1 (en)
CA (1) CA2623839C (en)
WO (1) WO2007038636A2 (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130203722A1 (en) 2006-09-26 2013-08-08 Rhonda R. Voskuhl Estriol therapy for autoimmune and neurodegenerative disease and disorders
US8658627B2 (en) 2001-04-25 2014-02-25 The Regents Of The University Of California Pregnancy hormone combination for treatment of autoimmune diseases
US20120328566A9 (en) * 2001-04-25 2012-12-27 Rhonda R Voskuhl Estrogen receptor ligand treatment for neurodegenerative diseases
US6936599B2 (en) 2001-04-25 2005-08-30 The Regents Of The University Of California Estriol therapy for multiple sclerosis and other autoimmune diseases
EP1928468A4 (en) * 2005-09-26 2010-12-08 Univ California ÖSTRIOL THERAPY AGAINST AUTOIMMUNE DISEASES AND NEURODEGENERATIVE ILLNESSES AND DISORDERS
US20100239528A1 (en) * 2007-07-20 2010-09-23 Stem Cell Therapeutics Corp. Treating or Ameliorating a Neuroinflammatory or Demyelinating Disorder with Prolactin and Interferon-Beta
JP5476587B2 (en) 2007-10-26 2014-04-23 アカディア ファーマシューティカルズ，インコーポレーテッド Condensed compounds having activity against estrogen receptors
HUP0800414A2 (en) * 2008-07-04 2010-10-28 Pecsi Tudomanyegyetem Pharmaceutical combination
CA2830519A1 (en) 2011-03-22 2012-09-27 The Population Council, Inc. Myelin regeneration with androgens
EP2653163A1 (en) * 2012-04-19 2013-10-23 Université de Liège Estrogenic components for use in the treatment of neurological disorders
US9808470B2 (en) 2012-04-19 2017-11-07 Universite De Liege Estrogenic components for use in the treatment of neurological disorders
WO2015168000A1 (en) 2014-04-28 2015-11-05 The Regents Of The University Of California Estrogen combination for treatment of multiple sclerosis
WO2015168002A1 (en) 2014-04-28 2015-11-05 The Regents Of The University Of California Pharmaceutical packaging for estriol therapy
US20170160174A1 (en) * 2014-06-27 2017-06-08 National University Corporation Nagoya University Embedding medium for specimen preparation, method for preparing curable base material nonpenetrating specimen, method for preparing curable base material penetrating specimen, curable base material nonpenetrating specimen, thin slice performance improver for frozen embedding medium, and frozen embedding medium
EP3188735A4 (en) 2014-09-02 2018-01-24 The Regents of the University of California Estrogen therapy for brain gray matter atrophy and associated disability
EP3189026B1 (en) * 2014-09-02 2020-07-22 The Regents of The University of California Estrogen receptor ligand treatment for neurodegenerative diseases
ES2957543T3 (en) 2014-09-29 2024-01-22 Univ California Compositions and methods to maintain cognitive function
WO2016160832A1 (en) 2015-03-30 2016-10-06 The Regents Of The University Of California Methods of monitoring estriol therapy
JP2019526612A (en) * 2016-09-12 2019-09-19 スティーブン・ホフマン Composition for treating dementia
JP7296315B2 (en) * 2016-11-15 2023-06-22 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Methods and apparatus for improving peripheral nerve function
EP3787633A1 (en) 2018-05-02 2021-03-10 Pantarhei Oncology B.V. Treatment of advanced estrogen receptor positive breast cancer
TW202124418A (en) * 2019-12-20 2021-07-01 比利時商埃斯特拉有限責任公司 Necroptosis modulators, screening methods and pharmaceutical compositions
CN113243332B (en) * 2020-02-07 2023-07-28 上海市东方医院（同济大学附属东方医院） Preparation and application of extensive brain area neuron tree sudden-breeding obstacle animal model
US12186564B2 (en) 2021-02-09 2025-01-07 The Regents Of The University Of California Methods and apparatuses for treating stroke using low-frequency stimulation

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5554601A (en) * 1993-11-05 1996-09-10 University Of Florida Methods for neuroprotection
US20010016325A1 (en) * 1999-12-01 2001-08-23 Mobley William C. Activation of novel estrogen receptor supports and neuronal viability and function

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9502921D0 (en) 1995-08-23 1995-08-23 Astra Ab New compounds
US6734211B1 (en) * 1999-07-09 2004-05-11 Oregon Health & Sciences University Compositions and methods for promoting nerve regeneration
AR027878A1 (en) * 1999-11-05 2003-04-16 Wyeth Corp METHODS FOR IDENTIFYING AND USING AMILOID INHIBITING COMPOUNDS
WO2002069976A2 (en) * 2001-03-02 2002-09-12 Stem Cell Therapeutics Inc. Use of ovarian hormone for increasing neural stem cell number
US6936599B2 (en) * 2001-04-25 2005-08-30 The Regents Of The University Of California Estriol therapy for multiple sclerosis and other autoimmune diseases
US20050209208A1 (en) * 2001-04-25 2005-09-22 The Regents Of The University Of California Use of estriol and other estranes, estrogens and estrogen receptor active compositions in the treatment of psoriasis and other autoimmune disorders
JP4801868B2 (en) * 2002-02-25 2011-10-26 晃史 山口 Systemic lupus erythematosus disease suppressant
EP1358881A1 (en) * 2002-04-30 2003-11-05 Schering Aktiengesellschaft Use of biogenic estriol diester prodrugs for the treatment of autoimmune diseases
EP1928468A4 (en) * 2005-09-26 2010-12-08 Univ California ÖSTRIOL THERAPY AGAINST AUTOIMMUNE DISEASES AND NEURODEGENERATIVE ILLNESSES AND DISORDERS

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5554601A (en) * 1993-11-05 1996-09-10 University Of Florida Methods for neuroprotection
US20010016325A1 (en) * 1999-12-01 2001-08-23 Mobley William C. Activation of novel estrogen receptor supports and neuronal viability and function

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BIEWENGA E ET AL: "Estradiol and raloxifene protect cultured SN4741 neurons against oxidative stress", NEUROSCIENCE LETTERS, vol. 373, no. 3, 20 January 2005 (2005-01-20), LIMERICK, IE, pages 179 - 183, XP004690113, ISSN: 0304-3940, DOI: 10.1016/J.NEULET.2004.09.067 *
KUMAR D M ET AL: "Role of nonfeminizing estrogen analogues in neuroprotection of rat retinal ganglion cells against glutamate-induced cytotoxicity", FREE RADICAL BIOLOGY AND MEDICINE, vol. 38, no. 9, 1 May 2005 (2005-05-01), ELSEVIER SCIENCE, US, pages 1152 - 1163, XP025352119, ISSN: 0891-5849, [retrieved on 20050501] *
OFFNER, HALINA: "Neuroimmunoprotective effects of estrogen and derivatives in experimental autoimmune encephalomyelitis: Therapeutic implications for multiple sclerosis", JOURNAL OF NEUROSCIENCE RESEARCH, vol. 78, no. 5, 28 October 2004 (2004-10-28), pages 603 - 624, XP002605593, ISSN: 0360-4012 *
PERRELLA, JOEL ET AL: "Protection of cortical cells by equine estrogens against glutamate-induced excitotoxicity is mediated through a calcium independent mechanism", BMC NEUROSCIENCE, vol. 6, 34, 10 May 2005 (2005-05-10), pages 17PP, XP002605592, ISSN: 1471-2202 *
SAMANTHA S SOLDAN ET AL: "Immune modulation in multiple sclerosis patients treated with the pregnancy hormone estriol", JOURNAL OF IMMUNOLOGY, vol. 171, no. 11, 1 December 2003 (2003-12-01), AMERICAN ASSOCIATION OF IMMUNOLOGISTS, US, pages 6267 - 6268, XP008126547, ISSN: 0022-1767 *
WEN, YI ET AL: "Transient Cerebral Ischemia Induces Aberrant Neuronal Cell Cycle Re-entry and Alzheimer 's Disease-like Tauopathy in Female Rats", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 279, no. 21, 24 February 2004 (2004-02-24), pages 22684 - 22692, XP002605887, ISSN: 0021-9258 *

Also Published As

Publication number Publication date
AU2006294662A1 (en) 2007-04-05
CA2623839C (en) 2013-12-17
JP2009510084A (en) 2009-03-12
EP3045177A1 (en) 2016-07-20
WO2007038636A3 (en) 2007-12-27
WO2007038636A2 (en) 2007-04-05
EP2698167A2 (en) 2014-02-19
EP1929291A2 (en) 2008-06-11
CA2623839A1 (en) 2007-04-05
EP2698167A3 (en) 2014-03-05

Similar Documents

Publication Publication Date Title
EP1929291A4 (en) ESTRIOL THERAPY FOR DISEASE OF AUTOIMMUNE AND NEURODEGENERATIVE DISORDERS
EP1434801A4 (en) TREATMENT FOR CENTRAL NERVOUS SYSTEM DISORDERS
IL178730A0 (en) New pharmaceutical compositions for the treatment of sexual disorders ii
EP1838320A4 (en) ANTAGONISTS OF CXCR4 FOR THE TREATMENT OF MEDICAL DISORDERS
ZA200606804B (en) Pharmaceutical composition for treatment of immunological disorders
MA28481B1 (en) Imidazole derivatives for the treatment of neurodegenerative disorders
EP1993365A4 (en) BIODAVAILABLE CURCUMINOID FORMULATIONS FOR TREATING ALZHEIMER'S DISEASE AND OTHER AGE ASSOCIATED DISORDERS
EP2430038A4 (en) METHODS AND COMPOSITIONS FOR TREATING NEURODEGENERATIVE DISORDERS AND ALZHEIMER'S DISEASE AND IMPROVING NORMAL MEMORY
FR13C0029I2 (en) COMPOSITIONS FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS
MA28555B1 (en) SUBSTITUTED MORPHOLINE DERIVATIVES FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS
EP1910829A4 (en) PREVENTION AND TREATMENT OF SYNUCLEINOPATHIC AND AMYLOIDOGENIC DISEASE
ZA200701277B (en) Arylidenes for the treatment of estrogen related receptor-alpha mediated diseases
EP1816913A4 (en) NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF CANCER AND DISORDERS ASSOCIATED WITH THE FUNCTION OF ANGIOGENESIS
EP1928468A4 (en) ÖSTRIOL THERAPY AGAINST AUTOIMMUNE DISEASES AND NEURODEGENERATIVE ILLNESSES AND DISORDERS
MA28791B1 (en) PIPERAZINE DERIVATIVES FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS
EP2421367A4 (en) ALLANTOIN ADMINISTRATION FOR THE TREATMENT OF NEURODEGENERATIVE DISEASE AND NEUROLOGICAL TRAUMATISM
EP1879616A4 (en) SYNTHESIS OF SUPERANTIBODIES AND USE FOR THE DETECTION, PREVENTION AND TREATMENT OF DISEASE
EP2691102A4 (en) HERBAL COMPOSITION FOR THE TREATMENT OF NEUROLOGICAL DISEASES AND THE IMPROVEMENT OF MEMORY DISORDERS
EP1673376A4 (en) TREATMENT OF BONE DISORDERS WITH SELECTIVE ANDROGEN RECEPTOR MODULATORS
MA28493B1 (en) Sulfonamides for the treatment of neurodegenerative disorders
EP1960549A4 (en) Fc-GAMMA POLYMORPHISMS FOR PREDICTING A DISEASE AND THE RESULTS OF TREATMENT
MA29085B1 (en) PROPHYLACTIC OR THERAPEUTIC AGENT FOR THE TREATMENT OF SLEEP DISORDERS
EP2180884A4 (en) CENTRAL ADMINISTRATION OF STABLE FORMULATIONS OF THERAPEUTIC AGENTS FOR THE TREATMENT OF CNS DISEASES
EP1988889A4 (en) COMPOSITIONS AND METHODS OF TREATMENT FOR OPHTHALMIC DISEASES AND DISORDERS
MA30901B1 (en) SEQUENTIAL COMBINATION THERAPY

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20080331

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK RS

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 45/06 20060101ALI20101022BHEP

Ipc: A61K 31/568 20060101ALI20101022BHEP

Ipc: A61K 31/566 20060101ALI20101022BHEP

Ipc: A61K 31/565 20060101ALI20101022BHEP

Ipc: G01N 33/00 20060101AFI20080408BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20101118

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20130122

REG Reference to a national code

Ref country code: DE

Ref legal event code: R003

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20151228